HighTower Advisors LLC Purchases Shares of 11,201 Hims & Hers Health, Inc. (NYSE:HIMS)

HighTower Advisors LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,201 shares of the company’s stock, valued at approximately $207,000.

A number of other large investors have also modified their holdings of HIMS. Quest Partners LLC grew its stake in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the 2nd quarter valued at $111,000. CWM LLC grew its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the last quarter. Amalgamated Bank increased its position in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares in the last quarter. Finally, Daiwa Securities Group Inc. acquired a new position in Hims & Hers Health in the second quarter valued at about $142,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Piper Sandler reiterated a “neutral” rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $22.80.

Hims & Hers Health Trading Up 2.0 %

NYSE:HIMS opened at $28.15 on Thursday. The stock has a 50 day simple moving average of $26.15 and a 200 day simple moving average of $21.41. Hims & Hers Health, Inc. has a 1-year low of $8.09 and a 1-year high of $35.02. The stock has a market cap of $6.15 billion, a P/E ratio of 63.98 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.04) earnings per share. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $19.57, for a total transaction of $1,149,737.50. Following the sale, the chief operating officer now directly owns 630,166 shares of the company’s stock, valued at $12,332,348.62. The trade was a 8.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 9,868 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $19.96, for a total value of $196,965.28. Following the transaction, the chief financial officer now directly owns 195,988 shares of the company’s stock, valued at approximately $3,911,920.48. This represents a 4.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,111,616 shares of company stock valued at $27,448,767. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.